Bristol-Myers Squibb Co (BMY) Enters Overbought Territory - Tale of the Tape

By
A A A

Bristol-Myers Squibb Co ( BMY ) has moved higher as of late, but there could definitely be trouble on the horizon for this company. That is because BMY is now in overbought territory with an RSI value of 70.60. Furthermore, estimates for the Bristol-Myers Squibb have been coming down, pushing it to Zacks Rank #4 (Sell). This suggests that investors may better off exiting this stock before it falls back to Earth.



BRISTOL-MYERS (BMY): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Investing Ideas , Stocks

Referenced Stocks: BMY

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

80%

Most Active by Volume

100,376,898
  • $17.62 ▲ 0.51%
83,231,837
  • $25.62 ▲ 1.91%
75,739,329
  • $111.78 ▼ 0.77%
65,297,937
  • $36.37 ▼ 1.76%
59,053,093
  • $47.66 ▲ 0.29%
53,482,350
  • $2.59 ▼ 0.38%
51,504,284
  • $7.34 ▲ 2.37%
51,434,656
  • $8.14 ▲ 6.96%
As of 12/19/2014, 04:15 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com